Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study

Christina Peters, Jean-Hugues Dalle, Franco Locatelli, Ulrike Poetschger, Petr Sedlacek, Jochen Buechner, Peter J Shaw, Raquel Staciuk, Marianne Ifversen, Herbert Pichler, Kim Vettenranta, Peter Svec, Olga Aleinikova, Jerry Stein, Tayfun Güngör, Jacek Toporski, Tony H Truong, Cristina Diaz-de-Heredia, Marc Bierings, Hany Ariffin, Mohammed Essa, Birgit Burkhardt, Kirk Schultz, Roland Meisel, Arjan Lankester, Marc Ansari, Martin Schrappe, IBFM Study Group;, Arend von Stackelberg, IntReALL Study Group, Adriana Balduzzi, I-BFM SCT Study Group, Selim Corbacioglu, EBMT Paediatric Diseases Working Party, Peter Bader, Christina Peters, Jean-Hugues Dalle, Franco Locatelli, Ulrike Poetschger, Petr Sedlacek, Jochen Buechner, Peter J Shaw, Raquel Staciuk, Marianne Ifversen, Herbert Pichler, Kim Vettenranta, Peter Svec, Olga Aleinikova, Jerry Stein, Tayfun Güngör, Jacek Toporski, Tony H Truong, Cristina Diaz-de-Heredia, Marc Bierings, Hany Ariffin, Mohammed Essa, Birgit Burkhardt, Kirk Schultz, Roland Meisel, Arjan Lankester, Marc Ansari, Martin Schrappe, IBFM Study Group;, Arend von Stackelberg, IntReALL Study Group, Adriana Balduzzi, I-BFM SCT Study Group, Selim Corbacioglu, EBMT Paediatric Diseases Working Party, Peter Bader

Abstract

Purpose: Total body irradiation (TBI) before allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with acute lymphoblastic leukemia (ALL) is efficacious, but long-term side effects are concerning. We investigated whether preparative combination chemotherapy could replace TBI in such patients.

Patients and methods: FORUM is a randomized, controlled, open-label, international, multicenter, phase III, noninferiority study. Patients ≤ 18 years at diagnosis, 4-21 years at HSCT, in complete remission pre-HSCT, and with an HLA-compatible related or unrelated donor were randomly assigned to myeloablative conditioning with fractionated 12 Gy TBI and etoposide versus fludarabine, thiotepa, and either busulfan or treosulfan. The noninferiority margin was 8%. With 1,000 patients randomly assigned in 5 years, 2-year minimum follow-up, and one-sided alpha of 5%, 80% power was calculated. A futility stopping rule would halt random assignment if chemoconditioning was significantly inferior to TBI (EudraCT: 2012-003032-22; ClinicalTrials.gov: NCT01949129).

Results: Between April 2013 and December 2018, 543 patients were screened, 417 were randomly assigned, 212 received TBI, and 201 received chemoconditioning. The stopping rule was applied on March 31, 2019. The median follow-up was 2.1 years. In the intention-to-treat population, 2-year overall survival (OS) was significantly higher following TBI (0.91; 95% CI, 0.86 to 0.95; P < .0001) versus chemoconditioning (0.75; 95% CI, 0.67 to 0.81). Two-year cumulative incidence of relapse and treatment-related mortality were 0.12 (95% CI, 0.08 to 0.17; P < .0001) and 0.02 (95% CI, < 0.01 to 0.05; P = .0269) following TBI and 0.33 (95% CI, 0.25 to 0.40) and 0.09 (95% CI, 0.05 to 0.14) following chemoconditioning, respectively.

Conclusion: Improved OS and lower relapse risk were observed following TBI plus etoposide compared with chemoconditioning. We therefore recommend TBI plus etoposide for patients > 4 years old with high-risk ALL undergoing allogeneic HSCT.

Figures

FIG 1.
FIG 1.
Patient enrollment, random assignment, and adherence to protocol. Other: Variable modifications of the given conditioning regimen due to medical reasons or center/parental decision. BU, busulfan; CHC, chemo-conditioning; CR, complete remission; MD, human leukocyte antigen (HLA)–compatible related or unrelated matched donor; MMD, mismatched donor; MSD, HLA-identical sibling donor; TBI, total body irradiation; Treo, treosulfan.
FIG 2.
FIG 2.
Primary end point: Overall survival. BU, busulfan; CHC, chemo-conditioning; CIR, cumulative incidence of relapse; EFS, event-free survival; OS, overall survival; TBI, total body irradiation; TREO, treosulfan; TRM, treatment-related mortality.
FIG 3.
FIG 3.
Secondary end points. BU, busulfan; CHC, chemo-conditioning; CIR, cumulative incidence of relapse; EFS, event-free survival; OS, overall survival; TBI, total body irradiation; TREO, treosulfan; TRM, treatment-related mortality.
FIG 4.
FIG 4.
Forrest plot showing subgroup analyses of overall survival by risk factor and conditioning regimen (ITT population). ALL, acute lymphoblastic leukaemia; BM, bone marrow, CR1, first complete remission (below 5% of morphological blasts in bone marrow; no active extramedullary disease); CR2, second complete remission; CR3, third complete remission; HSCT, haematopoietic stem cell transplantation; MD, human leukocyte antigen (HLA)-compatible (nine or 10 out of 10 allelic matches) related or unrelated matched donor; MRD, minimal residual disease; MSD, HLA-identical sibling donor; TBI, total body irradiation.

References

    1. Friend BD Bailey-Olson M Melton A, et al. : The impact of total body irradiation-based regimens on outcomes in children and young adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer 67:e28079, 2020
    1. Gao RW Dusenbery KE Cao Q, et al. : Augmenting total body irradiation with a cranial boost before stem cell transplantation protects against post-transplant central nervous system relapse in acute lymphoblastic leukemia. Biol Blood Marrow Transplant 24:501-506, 2018
    1. Hill-Kayser CE Plastaras JP Tochner Z, et al. : TBI during BM and SCT: Review of the past, discussion of the present and consideration of future directions. Bone Marrow Transplant 46:475-484, 2011
    1. Balduzzi A Dalle JH Wachowiak J, et al. : Transplantation in children and adolescents with acute lymphoblastic leukemia from a matched donor versus an HLA-identical sibling: Is the outcome comparable? Results from the International BFM ALL SCT 2007 Study. Biol Blood Marrow Transplant 25:2197-2210, 2019
    1. Dopfer R Henze G Bender-Gotze C, et al. : Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: Results of the German Cooperative Study. Blood 78:2780-2784, 1991
    1. Ifversen M Turkiewicz D Marquart HV, et al. : Low burden of minimal residual disease prior to transplantation in children with very high risk acute lymphoblastic leukaemia: The NOPHO ALL2008 experience. Br J Haematol 184:982-993, 2019
    1. Peters C Schrappe M von Stackelberg A, et al. : Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial. J Clin Oncol 33:1265-1274, 2015
    1. Dalle JH Balduzzi A Bader P, et al. : Allogeneic stem cell transplantation from HLA-mismatched donors for pediatric patients with acute lymphoblastic leukemia treated according to the 2003 BFM and 2007 International BFM Studies: Impact of disease risk on outcomes. Biol Blood Marrow Transplant 24:1848-1855, 2018
    1. Bunin N Aplenc R Kamani N, et al. : Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: A pediatric blood and marrow transplant consortium study. Bone Marrow Transplant 32:543-548, 2003
    1. Gupta T Kannan S Dantkale V, et al. : Cyclophosphamide plus total body irradiation compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with leukemia: A systematic review and meta-analysis. Hematol Oncol Stem Cell Ther 4:17-29, 2011
    1. Baker KS Leisenring WM Goodman PJ, et al. : Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation. Blood 133:2790-2799, 2019
    1. Lawitschka A, Peters C: Long-term effects of myeloablative allogeneic hematopoietic stem cell transplantation in pediatric patients with acute lymphoblastic leukemia. Curr Oncol Rep 20:74, 2018
    1. Saglio F Zecca M Pagliara D, et al. : Occurrence of long-term effects after hematopoietic stem cell transplantation in children affected by acute leukemia receiving either busulfan or total body irradiation: Results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) retrospective study. Bone Marrow Transplant:55:1918-1927, 2020
    1. Ansari M Theoret Y Rezgui MA, et al. : Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation. Ther Drug Monit 36:93-99, 2014
    1. Boztug H Zecca M Sykora KW, et al. : Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia. Ann Hematol 94:297-306, 2015
    1. Harris AC Boelens JJ Ahn KW, et al. : Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. Blood Adv 2:1198-1206, 2018
    1. Lee JW Kang HJ Kim S, et al. : Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients. Biol Blood Marrow Transplant 21:190-195, 2015
    1. Kato M Ishida H Koh K, et al. : Comparison of chemotherapeutic agents as a myeloablative conditioning with total body irradiation for pediatric acute lymphoblastic leukemia: A study from the pediatric ALL working group of the Japan Society for Hematopoietic Cell Transplantation. Pediatr Blood Cancer 62:1844-1850, 2015
    1. Zecca M Pession A Messina C, et al. : Total body irradiation, thiotepa, and cyclophosphamide as a conditioning regimen for children with acute lymphoblastic leukemia in first or second remission undergoing bone marrow transplantation with HLA-identical siblings. J Clin Oncol 17:1838-1846, 1999
    1. Glucksberg H Storb R Fefer A, et al. : Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18:295-304, 1974
    1. Kebriaei P Bassett R Lyons G, et al. : Clofarabine plus busulfan is an effective conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia: Long-term study results. Biol Blood Marrow Transplant 23:285-292, 2017
    1. Willasch AM Peters C Sedlacek P, et al. : Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy? A multicenter EBMT-PDWP study. Bone Marrow Transplant 55:1540-1551, 2020
    1. Bhatia S, Armenian SH, Landier W: How I monitor long-term and late effects after blood or marrow transplantation. Blood 130:1302-1314, 2017
    1. Shah NN Borowitz MJ Steinberg SM, et al. : Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 20:1033-1039, 2014
    1. Burke MJ Verneris MR Le Rademacher J, et al. : Transplant outcomes for children with T cell acute lymphoblastic leukemia in second remission: A report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 21:2154-2159, 2015
    1. Hamidieh AA Monzavi SM Kaboutari M, et al. : Outcome Analysis of pediatric patients with acute lymphoblastic leukemia treated with total body irradiation-free allogeneic hematopoietic stem cell transplantation: Comparison of patients with and without central nervous system involvement. Biol Blood Marrow Transplant 23:2110-2117, 2017
    1. Kalwak K Mielcarek M Patrick K, et al. : Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies. Bone Marrow Transplant 55:1996–2007, 2020
    1. Page KM Labopin M Ruggeri A, et al. : Factors associated with long-term risk of relapse after unrelated cord blood transplantation in children with acute lymphoblastic leukemia in remission. Biol Blood Marrow Transplant 23:1350-1358, 2017
    1. Mehta PA Zhang MJ Eapen M, et al. : Transplantation outcomes for children with hypodiploid acute lymphoblastic leukemia. Biol Blood Marrow Transplant 21:1273-1277, 2015
    1. Yanir AD Martinez CA Sasa G, et al. : Current allogeneic hematopoietic stem cell transplantation for pediatric acute lymphocytic leukemia: Success, failure and future perspectives-a single-center experience, 2008 to 2016. Biol Blood Marrow Transplant 24:1424-1431, 2018
    1. Locatelli F, Moretta F, Rutella S: Management of relapsed acute lymphoblastic leukemia in childhood with conventional and innovative approaches. Curr Opin Oncol 25:707-715, 2013
    1. McNeer JL Devidas M Dai Y, et al. : Hematopoietic stem-cell transplantation does not improve the poor outcome of children with hypodiploid acute lymphoblastic leukemia: A report from Children's Oncology Group. J Clin Oncol 37:780-789, 2019
    1. Schultz KR Bowman WP Aledo A, et al. : Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A children's oncology group study. J Clin Oncol 27:5175-5181, 2009
    1. Bader P Salzmann-Manrique E Balduzzi A, et al. : More precisely defining risk peri-HCT in pediatric ALL: Pre- vs post-MRD measures, serial positivity, and risk modeling. Blood Adv 3:3393-3405, 2019
    1. Eckert C Henze G Seeger K, et al. : Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol 31:2736-2742, 2013
    1. Pulsipher MA Langholz B Wall DA, et al. : The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: A phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. Blood 123:2017-2025, 2014
    1. Bernard F Auquier P Herrmann I, et al. : Health status of childhood leukemia survivors who received hematopoietic cell transplantation after BU or TBI: An LEA study. Bone Marrow Transplant 49:709-716, 2014
    1. Bresters D Emons JA Nuri N, et al. : Ovarian insufficiency and pubertal development after hematopoietic stem cell transplantation in childhood. Pediatr Blood Cancer 61:2048-2053, 2014
    1. Faraci M Diesch T Labopin M, et al. : Gonadal function after busulfan compared with treosulfan in children and adolescents undergoing allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 25:1786-1791, 2019

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren